A Phase 2 interventional study of KAE609 and KAE609 in Cure Rate, sponsored by Novartis Pharmaceuticals. Completed at 4 sites in 2 countries. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2015-09-10.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with acute P. falciparum infection after single dose with KAE609 at 75 mg, 150mg, 225mg and 300mg/day
the study is comprised of 4 sequential cohorts, in total there will be up to 48 patients enrolled in the study.
cohort 1: 6-12 patients receive 75mg single dose. cohort 2: 6-12 patients receive 150mg single dose. cohort 3: 6-12 patients receive 225mg single dose. cohort 4: 6-12 patients receive 300mg single dose. After approximately every 6 patients in any cohort have been treated with a given dose and complete the first 15 days, a safety and tolerability data review will be conducted by a Data Monitoring Committee(DMC). Consensus agreement of DMC is required to either escalate to the next dose level or expand a given cohort with an additional 6 patients in order to obtain more safety data.
23 studies on the registry are indexed under Parasitemia; 2 are open to participants now.
This study's enrollment of 11 is below the median of 64 across 15 interventional studies indexed under Parasitemia.
Browse Parasitemia studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
6-12 subjects with Plasmodium falciparum malaria will receive 75 mg KAE609 as a single dose
Drug: KAE609
6-12 subjects with Plasmodium falciparum malaria will receive 150 mg KAE609 as a single dose
Drug: KAE609
6 to 12 subjects with Plasmodium falciparum malaria will receive 225 mg KAE609 as a single dose
Drug: KAE609
6- 12 subjects with Plasmodium falciparum malaria will receive 300 mg KAE609 as a single dose
Drug: KAE609
28-day Cure Rate
28-day cure rate was measured by the endpoint of complete cure without recrudescence before Day 29. The primary variable of 28-day cure rate was defined as the proportion of patients with clearance of asexual parasitemia (by blood film) by day 6 of the study, and without subsequent recrudescence (by blood film).
Time frame: Day 28
| Milestone | Total - Cohort 1 |
|---|---|
| Started | 11 |
| Completed | 6 |
| Not completed | 5 |
| Withdrew: Unsatisfactory therapeutic | 5 |
28-day cure rate was measured by the endpoint of complete cure without recrudescence before Day 29. The primary variable of 28-day cure rate was defined as the proportion of patients with clearance of asexual parasitemia (by blood film) by day 6 of the study, and without subsequent recrudescence (by blood film).
| Percentage of participants | Total - Cohort 1 |
|---|---|
| 28-day Cure Rate | 63.67 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Total - Cohort 1 | — | 3/11 (27.3%) | 8/11 (72.7%) |
| Event | Total - Cohort 1 |
|---|---|
| Alanine aminotransferase increasedInvestigations | 2/11 |
| JaundiceHepatobiliary disorders | 1/11 |
| Aspartate aminotransferase increasedInvestigations | 1/11 |
| Event | Total - Cohort 1 |
|---|---|
| Platelet count decreasedInvestigations | 7/11 |
| Alanine aminotransferase increasedInvestigations | 5/11 |
| Aspartate aminotransferase increasedInvestigations | 4/11 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/11 |
| NauseaGastrointestinal disorders | 3/11 |
| HeadacheNervous system disorders | 3/11 |
| FatigueGeneral disorders | 2/11 |
| Blood alkaline phosphatase increasedInvestigations | 2/11 |
| DizzinessNervous system disorders | 2/11 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/11 |
| Age, Continuous(years) | Total - Cohort 1 |
|---|---|
| Mean | 31.6 ± 7.50 |
| Sex: Female, Male(Participants) | Total - Cohort 1 |
|---|---|
| Female | 0 |
| Male | 11 |
The record gives a start of Jul 2013, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NITD 609